Mesoblast Limited (ASX:MSB) Phase 3 Meeting Scheduled With FDA Following Positive Results Of Bone Marrow Regeneration Tr

  Melbourne, Australia, July 12, 2010 - (ABN Newswire) - Australian regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that based on positive results from its bone marrow transplant clinical trial, conducted at the University of Texas MD Anderson Cancer Center, a formal meeting has been scheduled with the United States Food and Drug Administration (FDA) to discuss a proposed Phase 3 clinical trial program.  

Sydney

  [ Change ]
 
Today

Min: 12°
Max: 19°
Possible afternoon shower.
Tomorrow

Min: 12°
Max: 19°
Possible afternoon shower.
 

Account

Login

To access your account and listings



Remember me
   
   
   
 
 
Find Hunter Valley accommodation online